Product Name: Human CTLA-8 / IL-17a Antibody (Perakizumab, Research Use)
Catalog Number: NBR-0629
Target Name: CTLA-8 / IL-17a
Trade Name: Perakizumab
Antibody Drug Description: Perakizumab is a recombinant humanized (from mouse) IgGκ monoclonal antibody (mAb) binds to and neutralises the proinflammatory cytokine interleukin-17A (IL-17A). It was discovered and developed by Roche/Genentech) with the developmental name RG4934 (RO5310074), for the treatment of autoimmune diseases such as psoriasis, psoriatic arthritis, ankylosing spondylitis, multiple sclerosis and inflammatory arthritis. Appearance: Transparent Liquid
Molecular Weight: ~150kDa
CAS：N/A
Solubility: Water; PBS, TBS Buffer etc.
Expression System: CHO Expressed
Isotype of Ab: Ab. Isotype - IgG

  Gene Name: CTLA-8
Synonyms: IL-17A; IL-17; CTLA8
Target Description: IL17A (Interleukin 17A) is a Protein Coding gene. Diseases associated with IL17A include Allergic Contact Dermatitis and Bronchiolitis Obliterans. Among its related pathways are MIF Mediated Glucocorticoid Regulation and TGF-Beta Pathway. Gene Ontology (GO) annotations related to this gene include cytokine activity. An important paralog of this gene is IL17F.
Ensembl: ENSG00000112115
Uniprot:  Q16552